Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication

This article was originally published in PharmAsia News

Executive Summary

Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia

You may also be interested in...



Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin

TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai

Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin

TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai

Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook

TOKYO - Having no large extra charges for acquisitions like its Japanese competitors, Astellas Pharma predicted Nov. 5 revenues and earnings for fiscal 2008 would be slightly better than its earlier forecast but the yen's appreciation and slow new drug launches would nudge the performance modestly lower than in the preceding business year

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel